English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduReston, VA (Embargoed until 5:00 p.m. EDT, Sunday, June 13, 2021) – A new imaging technique has the potential to detect neurological disorders–such as Alzheimer’s disease–at their earliest stages, enabling physicians to diagnose and treat patients more quickly. Termed super-resolution,…
Tag: Alzheimer’s Disease
Study Identifies How COVID-19 Linked to Alzheimer’s Disease-like Cognitive Impairment
A new Cleveland Clinic-led study has identified mechanisms by which COVID-19 can lead to Alzheimer’s disease-like dementia. The findings, published in Alzheimer’s Research & Therapy, indicate an overlap between COVID-19 and brain changes common in Alzheimer’s, and may help inform risk management and therapeutic strategies for COVID-19-associated cognitive impairment.
Memory Biomarkers Confirm Aerobic Exercise Helps Cognitive Function in Older Adults
Until now, systemic biomarkers to measure exercise effects on brain function and that link to relevant metabolic responses were lacking. A study shows a memory biomarker, myokine Cathepsin B (CTSB), increased in older adults following a 26-week structured aerobic exercise training. The positive association between CTSB and cognition, and the substantial modulation of lipid metabolites implicated in dementia, support the beneficial effects of exercise training on brain function and brain health in asymptomatic individuals at risk for Alzheimer’s.
Largescale brain epigenetics study provides new insights into dementia
The largest study of its kind has unveiled new insights into how genes are regulated in dementia, including discovering 84 new genes linked to the disease.
Study identifies how COVID-19 linked to Alzheimer’s disease-like cognitive impairment
Cleveland Clinic-led research team used artificial intelligence to uncover association between COVID-19 and brain changes
Forget me not: Novel target shows promise in treating Alzheimer’s and related dementias
A novel tau protein conformation, cis P-tau, is a toxic early driver of Alzheimer’s disease and related dementias and silencing of this protein through immunotherapy ameliorates dementia symptoms in preclinical models
Could naked mole rats hold key to curing cancer and dementia?
Researchers say rodent has unique DNA repair mechanism
‘Roadmaps’ of the brain reveal regions vulnerable to Alzheimer’s disease
GRAND RAPIDS, Mich. (JUNE 10, 2021) — Much like a supply truck crossing the countryside, the misfolded proteins that damage neurons in Alzheimer’s disease travel the “roads” of the brain, sometimes stopping and sometimes re-routing to avoid roadblocks, reports a…
Research News Tip Sheet: Story Ideas from Johns Hopkins Medicine
NEWS STORIES IN THIS ISSUE:
– Study Says Failure to Rid Amyloid Beta Protein from Brain May Lead to Alzheimer’s Disease
– Johns Hopkins Medicine Team Discovers Novel Mediator of Once Mysterious Chronic Itch – Study Suggests Molecular Changes in Tissue Microenvironment May Promote Colorectal Cancer
– Researchers ID Anti-Inflammatory Proteins as Therapy Targets for Nasal and Sinus Problem
– Johns Hopkins Children’s Center Receives NIH Award to Study Dangerous Pediatric Disease
Elemental copper and iron found within the brains of deceased Alzheimer’s patients
Biogenic metallic elements in the human brain?
New Drug for Alzheimer’s Patients Provides Hope With Caution
Nikhil Palekar,* MD, Associate Professor of Psychiatry, Director of Geriatric Psychiatry, and Medical Director of the Center for Excellence for Alzheimer’s Disease at the Renaissance School of Medicine at Stony Brook University, is available to discuss the newly approved FDA…
Harnessing healthy behaviors to prevent dementia
The approval of a new Alzheimer’s disease drug is getting a lot of attention, but a recent scientific review of the evidence about dementia prevention shows an important role for primary care providers and patients to modify risk factors and protect brain health over the long term.
Rutgers Expert Available to Discuss New FDA Approved Drug for Alzheimer’s
A Rutgers neurologist William T. Hu is available to discuss the new drug, Aduhelm, approved by the Food and Drugs Administration to treat Alzheimer’s. “While there is still a lot of work to be done in understanding this drug, we…
Scientists discover immune cell behavior that plays a key role in Alzheimer’s disease
A new study has pinpointed a small group of cells in the brain which could be crucial to understanding how Alzheimer’s disease begins and how to slow its progression. This discovery could help research into treatment for the disease by…
Weak brain waves may warn of age-related neurodegenerative disease
People with mild cognitive impairment or Alzheimer’s disease have weaker gamma waves in their brain than healthy peers, a discovery that may lead to new ways to diagnose these conditions
To prevent delirium, increase mobility, connection and sleep
Interventions result in shorter hospital stays, reduced readmissions, UCSF study shows
A genomic single-cell map explains neuronal death in epilepsy
An interdiscipinary collaboration lead by CSIC deciphers the genetic map of hippocampal sclerosis, a key finding for the diagnosis of temporal lobe epilepsy
University of Maryland Medical Center neurologist available for interviews about new Alzheimer’s Disease drug
News outlets: In your coverage of the historic FDA approval of aducanumab, the first drug approved for disease modification of Alzheimer’s Disease, not just treatment of symptoms, please consider speaking with University of Maryland Medical Center neurologist Dr. Julia Biernot.…
Good afternoon, the FDA today approved aducanumab–the first new therapy for Alzheimer’s in 13 years. University of Miami expert Dr. James Galvin would be great for an interview.
Good afternoon, the FDA today approved aducanumab–the first new therapy for Alzheimer’s in 13 years. University of Miami experts, Including Dr. James Galvin, led clinical trials to test the pioneering drug with patients and can discuss why the aducanumab is…
Renowned Alzheimer’s Clinical Trials Researcher Available to Comment on June 7 FDA Approval of Aducanumab
The Food and Drug Administration on June 7 approved Aducanumab, which will carry the brand name Aduhelm, as the first new treatment for Alzheimer’s disease in nearly 20 years. Dr. Jeffrey L. Cummings, UNLV research professor and leading expert on Alzheimer’s clinical trials, calls…
FAU’s Ruth Tappen Named ‘2021 Alliance World Class Faculty’ Honoree
Ruth M. Tappen, Ed.D., RN, FAAN, the Christine E. Lynn Eminent Scholar and professor in FAU’s Christine E. Lynn College of Nursing, is nationally and internationally renowned as an innovative researcher and scholar. Tappen was recently recognized as the “2021 Alliance World Class Faculty” honoree by the Greater Fort Lauderdale Alliance.
Researchers identify a molecule critical to functional brain rejuvenation
The discovery could have important implications for the health of aging brains and development of therapies for neurodegenerative diseases
Simple blood test can accurately reveal underlying neurodegeneration
A single biomarker can accurately indicate the presence of underlying neurodegeneration in people with cognitive issues
Alzheimer’s Drug Discovery Foundation statement on FDA approval of aducanumab
New York, NY (June 7, 2021) – Today’s FDA approval of the monoclonal antibody Aduhelm (aducanumab) to treat patients with Alzheimer’s disease reflects years of significant advances in Alzheimer’s research. This is the first new Alzheimer’s drug approved in 17…
A Computational Look at How Genes Change the Human Brain
Pitt Engineer’s research will focus on better understanding the mechanisms behind Alzheimer’s disease and other neurological disorders
FDA to Decide on Alzheimer’s Drug Approval – During National Alzheimer’s & Brain Awareness Month
It is estimated that someone in America will develop Alzheimer’s disease every 67 seconds. As many as 500,000 new cases of Alzheimer’s disease are expected to be diagnosed this year. With no known cure, the Food & Drug Administration is…
New research may offer hope for Alzheimer’s patients
University of Kentucky Neuroscience Professor Greg Gerhardt’s new research program will provide answers to long-standing questions about the role of neurotransmitters GABA and glutamate in the progression of Alzheimer’s disease. A culmination of his nearly 40 years of brain research, Gerhardt’s study could help to develop new treatments for the disease.
New University of Kentucky research may offer hope for Alzheimer’s patients
LEXINGTON, Ky. (June 4, 2021) — University of Kentucky Department of Neuroscience Professor Greg Gerhardt, Ph.D., hypothesizes that the balance of glutamate and gamma-aminobutyric acid (GABA) — two main neurotransmitters in the brain — contributes to Alzheimer’s disease and age-related…
Secondary infections inflame the brain, worsening cognition in Alzheimer’s disease
New research into Alzheimer’s disease (AD) suggests that secondary infections and new inflammatory events amplify the brain’s immune response and affect memory in mice and in humans – even when these secondary events occur outside the brain.
Expert Available on How Early Menopause May Increase the Risk of Alzheimer’s
Ernestine A. Wright, M.D., FACP, is a primary care physician who can talk to the media about how early menopause could increase a woman’s risk of getting Alzheimer’s. Dr. Wright provides care for adults aged 21 years and upwards – providing…
Secondary infections inflame the brain, worsening cognition in Alzheimer’s disease
New research into Alzheimer’s disease (AD) suggests that secondary infections and new inflammatory events amplify the brain’s immune response and affect memory in mice and in humans – even when these secondary events occur outside the brain. Scientists believe that…
Alzheimer’s disease raises the risk of severe COVID-19 and death from this viral disease
Patients with dementia and especially Alzheimer’s run a threefold risk of dying as a result of infection by SARS-CoV-2. The risk is six times greater if they are over 80, according to a study by Brazilian researchers
Elevating African cichlid fish as a scientific model of social disorders
University of Houston researcher wins prestigious Beckman Young Investigator Award
Studies reveal skull as unexpected source of brain immunity
Immune cells from skull bone marrow guard the brain, spinal cord
Rush Researchers Develop New Measure of Brain Health
A new measure of brain health developed by researchers at Rush University Medical Center may offer a novel approach to identifying individuals at risk of memory and thinking problems, according to research results published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association on June 1.
Modulating rapamycin target protein promotes autophagy, lowering toxic Huntingtin protein
Experiments with small molecule have implications for research on aging.
Role of sleep-related brain activity in clearing toxic proteins and preventing Alzheimer’s disease
Global brain activity seen on fMRI, and its connection with cerebrospinal fluid flow weaker in brains of individuals with Alzheimer’s disease risk or related toxin buildup
Alzheimer’s: Blood oxygen levels could explain why memory loss is an early symptom
In a world first, scientists from the University of Sussex have recorded blood oxygen levels in the hippocampus and provided experimental proof for why the area, commonly referred to as ‘the brain’s memory centre’, is vulnerable to damage and degeneration,…
Changes in how cholesterol breaks down in the body may accelerate progression of dementia
Study suggests that some cholesterol medications may impact signaling pathways in the brain, particularly in men
Novel approaches in treating neurodegenerative disorders
The central nervous system (CNS) is the most vital component of our body, regulating various kinds of daily activities that are essential for our life processes. Keeping the balance between body and brain and maintaining the homeostasis of CNS is…
Scientists find a way to detect the spectral signals of amyloid fibrils
It will help to better understand the mechanism of neurodegenerative diseases
Amazon indigenous group’s lifestyle may hold a key to slowing down aging
Tsimane people are unique for their healthy brains that age more slowly
First clinical trial to assess Alzheimer’s gene therapy receives $5 million
The National Institute on Aging (NIA), part of the National Institutes of Health, has awarded a $5 million grant to researchers at University of California San Diego School of Medicine to conduct a first-in-human Phase 1 clinical trial of a…
Nonprofits, federal government surpass pharma to lead Alzheimer’s drug development
Two articles published online today by Alzheimer’s & Dementia: Translational Research & Clinical Interventions , a journal of the Alzheimer’s Association, show substantial changes in the focus and funding of clinical trials for Alzheimer’s disease therapies. The newly published articles…
‘Rejuvenating’ the Alzheimer’s brain
Alzheimer’s disease is the main cause of dementia and current therapeutic strategies cannot prevent, slow down or cure the pathology. The disease is characterized by memory loss, caused by the degeneration and death of neuronal cells in several regions of…
Hackensack Meridian Health and Eisai Inc. Join Forces to Support the Expansion of Alzheimer’s Disease Detection and Services for Patients
Hackensack Meridian Health and Eisai Inc. Join Forces to Support the Expansion of Alzheimer’s Disease Detection and Services for Patients
Link between local oxygen depletion in the brain and Alzheimer’s disease
The study, published in the journal Nature Aging and led by the laboratories of Dr. Alberto Pascual (CSIC), from the Neuronal Maintenance Mechanisms Group, and Prof. Javier Vitorica (University of Seville/CIBERNED) of the Physiopathology of Alzheimer’s Disease Group at IBiS,…
Simple diagnostic tool predicts individual risk of Alzheimer’s
Researchers at Lund University in Sweden have developed an algorithm that combines data from a simple blood test and brief memory tests, to predict with great accuracy who will develop Alzheimer’s disease in the future. The findings are published in…
Step-closer to nasal spray drug delivery for Parkinson’s disease
Scientists at the University of York have made significant progress in the development of a nasal spray treatment for patients with Parkinson’s disease. Researchers have developed a new gel that can adhere to tissue inside the nose alongside the drug…
Scientists discover gene signature for plaque-eating microglia in Alzheimer’s Disease
SINGAPORE, 21 May 2021 – Alzheimer’s Disease is the most common form of dementia and is characterised by the build-up of amyloid plaques in the brain. Microglia, the immune sentinels of the brain, are not only responsible for eliminating foreign…